|
||
|
Venture capital firms and funds in Europe 128 Venture Capital Group 3i Venture Capital Accuitive Medical Acer Venture Capital Act Venture Capital Ltd Adelaide Venture Capital Email ADS Ventures Boston Advantages Of Venture Capital Advent Venture Capital Agio Capital Alabama Venture Capital Alaska Venture Capital All Stages Venture Capital American Venture Capital Analysis Venture Capital Analyze Venture Capital Angel Capital Appraisal Venture Capital Arch Venture Capital Argentina Venture Capital Arizona Venture Capital Arkansas Venture Capital Arrowpath Venture Capital Assess Venture Capital Assessment Venture Capital Atlas Venture Capital ATV Venture Capital Aurora Fund Australia Venture Capital Austria Venture Capital Automotive Venture Capital AZ Venture Capital VCgate More Venture Capital Terms and Topics
-
IDev Technologies, Inc. Closes $19 Million Financing
November 28th, 2006 No comments
IDev Technologies, Inc., an emerging leader in the development and marketing of minimally invasive stent systems for the treatment of peripheral vascular and non-vascular diseases, recently announced that it has closed a $19 million Series B round of financing. Three new investors joined the financing: Rivervest Venture Partners, Bay City Capital and Heron Capital. Additionally, existing investors including PTV Sciences, members of the senior management team and advisors to the company also participated. Dennis Wahr, MD from Rivervest and Jeanne Cunicelli from Bay City Capital have been appointed to the IDev Board of Directors.
Thomas M. Tully, Chairman and CEO, commented, “We are very pleased to have completed this financing with the addition of Rivervest, Bay City Capital and Heron as new investors. This additional capital will allow us to aggressively execute on our commercialization and clinical trial plans for the SUPERA™ stent in the US and Europe beginning in early 2007.”
SUPERA™ represents an advance over traditional laser cut nitinol tube stents in offering more than significantly greater radial strength than the next strongest offering. The increase in radial strength is due to the product’s novel interwoven nitinol wire design. Unlike traditional laser cut nitinol tube stents, the interwoven nitinol wire design allows for enhanced product strength without compromising product flexibility. SUPERA™ has been tested and proven to withstand over 10,000,000 cycles of repeated bending and flexing to 120 degrees without fracture in an engineering bench fatigue study. The combined benefits of enhanced radial strength and flexibility are expected to improve product durability for patients by reducing the incidence of stent kinking, crushing and fracturing. Additionally, the unique delivery system allows for precise placement and repositionability prior to deployment. The stent has been 510(k) approved by the FDA for relief of biliary strictures and CE Mark approved for both peripheral vascular and non-vascular applications.
For more information, please visit: www.idevmd.com
Leave a reply
Latest Headlines:
Friday August 31, 2012
Zscaler Secures $38 Million Investment Round
Wednesday November 30, 2011
Health Care Solutions companies Infinity Pharmaceutics, NanoVobronix and Selventa raise funds.
Monday November 21, 2011
Panda Power opens $420 Million Fund for Solar and Natural Gas Projects
Thursday November 17, 2011
Better Place raises $200 Million for Electric Cars in the Series C of Funding
Wednesday November 16, 2011
Accel Partners raise $100 Million Big Data Fund to Invest in Hadoop, NoSQL and other Companies
Tuesday November 15, 2011
Skimlinks raises $4.5 Million to help Bloggers Increase their Gains
Monday November 14, 2011
Standing Cloud raises $3 Million to help New Cloud Providers grow Faster
Thursday November 10, 2011
Zillow acquires Diverse Solutions for $7.8 to help Real Estate Agents increase their Visibility